Capital Flow Monitor · Sponsors · CIK 1865257
Allyx Therapeutics, Inc.
555 Long Wharf Drive, NEW HAVEN, CT, 06511 · (908) 432-2845
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$30.0M
Sold
$26.4M
% sold
88.1%
Investors
32
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | D ·current | 506(b) | $30.0M | $26.4M | 88.1% | 32 | EDGAR ↗ |
| 2026-03-03 | D | 506(b) | $4.0M | $3.3M | 83.1% | 12 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Stephen Bloch — Executive Officer / Director, New Haven, CT
1 other raise
- Onkos Surgical, Inc. $37.2M of $37.2M · 100.0%
- Stephen Strittmatter — Director, New Haven, CT
-
Paul Fonteyne — Director, New Haven, CT
3 other raises
- DalCor Pharmaceuticals US, LLC $7.0M of $7.0M · 100.0%
- Apnimed, Inc. $35.0M of $35.0M · 100.0%
- Triton Therapeutics, Inc. $36.4M of $36.4M · 100.0%
- Gregory P Ho — Director, New York, NY
- Robert A Bettigole — Director, New Haven, CT
- Timothy Siegert — Executive Officer, New Haven, CT
-
Kevin L. Rakin — Director, Westport, CT
1 other raise
- CapeHaven Holding Company, LLC $1.4M of $5.0M · 28.9%
Placement agents
- Supervision Partners Llc · 0 RE raises
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.